Pyxis Oncology, Inc. Business Combination, Acquisition Related Costs
Pyxis Oncology, Inc. (PYXS) reported Business Combination, Acquisition Related Costs of $1.00 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2023-11-07
- Pyxis Oncology, Inc. business combination, acquisition related costs for the quarter ending 2023-09-30 was $1.00M.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 9 month |
|---|---|---|
| 2023-09-30 | $1.00M 10-Q · filed 2023-11-07 | $1.30M 10-Q · filed 2023-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |